The ability of radial glial progenitors (RGPs) to generate cortical neurons is determined by local extracellular factors and signaling pathways intrinsic to RGPs. Here we find that GPR157, an orphan G protein-coupled receptor, localizes to RGPs' primary cilia exposed to the cerebrospinal fluid (CSF). GPR157 couples with Gq-class of the heterotrimeric G-proteins and signals through IP 3 -mediated Ca 2+ cascade. Activation of GPR157-Gq signaling enhances neuronal differentiation of RGPs whereas interfering with GPR157-Gq-IP 3 cascade in RGPs suppresses neurogenesis. We also detect the presence of putative ligand(s) for GPR157 in the CSF, and demonstrate the increased ability of the CSF to activate GPR157 at neurogenic phase. Thus, GPR157-Gq signaling at the primary cilia of RGPs is activated by the CSF and contributes to neurogenesis.
When brain coronal sections were immunostained with this antibody, GPR157 immunofluorescent signals were detected around the luminal surface of the ventricular zone (VZ) in the developing neocortex at E13 (Fig. 1B) . Detailed immunohistochemical analyses revealed that punctate GPR157 immunofluorescent signals were detected outside of the ventricular surface. Noticeably, they overlapped with staining signals of acetylated tubulin (Ac-TUB; Fig. 1C ) that is assembled in the axonemes of the primary cilia of RGPs in the developing neocortex 20 . Almost no GPR157 immunofluorescent signals were detected in sections immunostained with antibody pre-incubated with its immunogen (Supplementary Fig. S2 ). In addition, GPR157 signals were not detected in regions enriched with TBR2-positive intermediate progenitors 21 and β III-tubulin (TUJ1)-positive neurons ( Supplementary Fig. S3 ). These results suggest that GPR157 is enriched in RGPs and unlikely expressed in intermediate progenitors/neurons.
We went on to study the developmental expression of GPR157 in E10, E17, P0 and adult neocortex. At E10, GPR157 immunofluorescent signals showed significant overlap with Ac-TUB signals at the ventricular surface, similar to those at E13 (Supplementary Fig. S4 ). In E17, P0, and adult neocortex, no GPR157 signal was observed at the ventricular surface but also in the entire cerebral wall (Supplementary Fig. S4 ). This result is consistent with the undetectable expression of Gpr157 mRNA in the P0 neocortex and suggests preferential expression of GPR157 during the early to mid stages of corticogenesis.
Given that GPR157 immunoreactivity overlapped with Ac-TUB, the en face view of the ventricular surface of neocortices stained with GPR157 antibody was imaged in order to refine the expression pattern of GPR157 in the primary cilia of RGPs. For this, E13 neocortices were electroporated with Lifeact-EGFP (MGVADLIKKFESISKEE-EGFP) to label F-actin that is assembled in the adherens junctions within the apical side of the descending processes of RGPs 22 (see also the diagram in Fig. 1D) . The cortices were then immunostained with antibodies against GPR157 and Ac-TUB. The en face view showed a honeycomb-like organization of F-actin. Ac-TUB immunofluorescent signals were detected around the center of F-actin rings. GPR157 immunoreactivity shows significant overlap with Ac-TUB signals. Of note, GPR157 immunoreactivity appears to not uniformly localize along the entire length of the primary cilia. This raises the possibility that GPR157 is enriched in specific subdomains in the cilia. Such enrichment has been previously observed for several certain ciliary membrane 23 . Specificity of the GPR157 antibody for staining of brain sections was confirmed with brains electroporated with the small hairpin RNA (shRNA) against Gpr157 transcript (see below). While Ac-TUB and F-actin were clearly detected in GPR157 shRNA-introduced cells, GPR157 signals were remarkably diminished (Fig. 1D) . Together, these results indicate that GPR157 localizes to the primary cilia of RGPs in the developing neocortex.
GPR157 knockdown inhibits neuronal differentiation of RGPs.
We investigated a potential role for GPR157 in RGPs of developing neocortex (Fig. 2 ). For this, we generated shRNA expression constructs targeting Gpr157 transcript. We identified two different shRNA constructs (shRNA#1, shRNA#2) capable of knocking down expression of GPR157 transiently expressed in U-2 OS cells ( Supplementary Fig. S1 ). Contrariwise, expression of GPR157 with two silent mutations within the target sequence of shRNA#2 (GPR157 res ) was not affected by the shRNA (Supplementary Fig. S1 ).
We then co-introduced either control or GPR157 shRNA constructs with the GFP-expression plasmid, into the VZ of the E13 neocortex by in utero electroporation, and harvested the embryos 48 hours later (at E15). In GPR157 shRNA-electroporated neocortices, a larger population of GFP-positive cells remained PAX6-positive RGPs when compared with the population found in control shRNA-expressing neocortices (Fig. 2) . When RGPs were pulse-labeled with 5-bromo-2-deoxyuridine (BrdU) for 30 minutes, the BrdU-positive fraction of GFP-labeled PAX6-positive RGPs was not significantly changed upon introduction of GPR157 shRNAs ( Supplementary Fig. S5 ). These results suggest that the increased population of RGPs upon introduction of GPR157 shRNA is not due to enhanced proliferation but rather to impaired differentiation.
To determine whether neuronal differentiation of progenitors is impaired upon GPR157 knockdown, we assessed the production of intermediate progenitors by immunohistochemistry using an antibody against TBR2. We found a significant reduction in the fraction of TBR2-positive intermediate progenitors in GPR157 shRNA-introduced neocortices when compared to control shRNA-expressing neocortices (Fig. 2) . Altogether, these observations suggest that introduction of the GPR157 shRNA in RGPs impairs their neuronal differentiation in the developing neocortex. To confirm that impaired neurogenesis results specifically from GPR157 knockdown, we performed a rescue experiment by overexpressing GPR157 res . Expression of GPR157 mutant almost completely reversed the phenotypes caused by GPR157 shRNA#2, i.e. the abnormal increase in PAX6 population and decrease in TBR2 fraction (Fig. 2) . There was no significant difference in the percentage of apoptotic cells among the GFP-positive cells at any condition (<1%), thereby excluding apoptosis as an explanation for the observed phenotypes. Taken together, these results confirm that impaired neurogenesis in GPR157 shRNA-introduced RGPs is caused by loss of GPR157 function.
We also examined the fate of GPR157-depleted cells at later neurodevelopmental stages. For this, we co-electroporated GFP-expressing plasmid with either control or GPR157 shRNA constructs at E14, and embryos were harvested at E17. In control neocortices, the majority of GFP-labeled cells were present in the cortical plate (CP) and the intermediate zone (IZ). In GPR157 shRNA-electroporated neocortices, a significantly larger population of GFP-positive cells was observed in the IZ and VZ while a fewer fraction was in the CP when compared to populations found in control neocortices ( Supplementary Fig. S6 ). We next determined whether the redistribution of cells is correlated with altered neuronal differentiation using immunostaining with TUJ1 antibody. We found a significant reduction in the fraction of TUJ1-positive neurons in GPR157 shRNA-introduced neocortices ( Supplementary Fig. S6 ). Altogether, these observations suggest that GPR157 depletion in RGPs results in a decreased propensity of RGPs to differentiate into intermediate progenitors (Fig. 2 ) and consequently neurons ( Supplementary Fig. S6 ). As almost all GFP-labeled cells in the VZ of GPR157 shRNA-introduced neocortices were negative for TUJ1 and a sizable fraction of the GFP-labeled cells were in the CP, redistribution of these cells is unlikely due to migration defects of neurons.
GPR157 couples with Gq-class of heterotrimeric G-proteins. Most of GPCRs transduce extracellular signals into cells via activation of heterotrimeric G-proteins. Gα protein family can be grouped into four subfamilies (Gα s, Gα i, Gα q, Gα 12/13) with distinct signaling pathways 13 . It is known that overexpression of GPCRs leads to ligand-independent activation of their cognate G-proteins 24 . We found that overexpression of GPR157 induces an increase in intracellular calcium concentration ([Ca 2+ ] i ) in U-2 OS cells (Fig. 3A,D) . We wanted to determine whether of ectopic GPR157 has similar effects on [Ca 2+ ] i in cultured RGPs. Following in utero co-electroporation of E13 RGPs with either control or GPR157-expressing plasmid and GFP-expressing plasmid, GFP-labeled cells were cultured and changes in [Ca 2+ ] i in these cells were measured 24 hours later. We found that overexpression of GPR157 induces an increase in [Ca 2+ ] i in GFP-labeled cells ( Supplementary Fig. S7 ). Since almost all GFP-labeled cells (> 96%) were SOX2-positive RGPs ( Supplementary Fig. S7 ), we concluded that overexpression of GPR157 increase [Ca 2+ ] i in RGPs, like in U-2 OS cells. Since the major downstream pathway of Gα q converges to Ca 2+ release from intracellular Ca 2+ stores through the activation of the PLC-IP 3 pathway 25 , we determined whether GPR157-evoked increase in [Ca 2+ ] i is mediated via Gq-signaling. Peptides corresponding to C-terminal regions of Gα (Gα -CTs) can act as competitive blockers for GPCR-G protein signaling as they selectively bind to the G protein-binding site on cognate GPCRs and attenuate the signaling through a given G protein 26 . When Gα q-CT was co-expressed with GPR157, GPR157-induced augmentation in [Ca 2+ ] i was partially prevented (Fig. 3A,D ). These observations indicate that GPR157 is coupled with Gq-class of heterotrimeric G-proteins.
To determine whether [Ca 2+ ] i elevation elicited by GPR157-Gq was mediated by IP 3 , we used IP 3 trapping protein (IP 3 sponge) to sequester IP 3 and suppress IP 3 receptor-mediated Ca 2+ release 27 . When the IP 3 sponge was co-expressed with GPR157, GPR157-induced elevation in [Ca 2+ ] i was almost completely suppressed ( Fig. 3B,E) . Like overexpression of GPR157, introduction of constitutively active Gα q (Gα q Q209L) in U-2 OS cells increased [Ca 2+ ] i . Such increase was almost completely suppressed with co-expression of IP 3 sponge (Fig. 3C,F) . Altogether, these results suggest that GPR157 couples with Gq and activates PLC-IP 3 Gq and IP 3 regulates neuronal differentiation of RGPs. Given that GPR157 signals through Gq-IP 3 -mediated signaling (Fig. 3) , we next examined whether alterations in Gq-IP 3 -mediated signaling recapitulate the effects of GPR157 depletion in vivo. Similarly to GPR157 knockdown, introduction of Gα q-CT or IP 3 sponge increased the fraction of PAX6-positive cells and decreased the fraction of TBR2-positive cells when compared to controls (Fig. 4A-D) . In addition, the BrdU-positive fraction of GFP-labeled PAX6-positive RGPs was not significantly changed by Gα q-CT and IP 3 sponge, indicating that cell cycle progression of RGPs was not affected (Supplementary Fig. S8 ).
Next, we asked whether GPR157 signaling regulates neuronal differentiation of cultured RGPs. For this purpose, E13 embryos were co-electroporated with GFP and GPR157, cultured for 3 days, and immunostained with antibodies against TUJ1 and SOX2. The vast majority (85%) of control GFP-labeled cells were SOX2-positive RGPs, and the remaining cells (15%) were TUJ1-positive neurons. On the other hand, GPR157 overexpression gave rise to more than 30% of TUJ1-positive neurons (Fig. 4E,G) . Given that neuronal differentiation (Fig. 4E ,G) and [Ca 2+ ] i in cultured RGPs ( Supplementary Fig. S7 ) were enhanced upon activation of GPR157 signaling, we asked the question whether GPR157, Gq, and IP 3 regulate neuronal differentiation through the same pathway. To do so, we looked at the effects of Gα q-CT and IP 3 sponge on GPR157-mediated neuronal differentiation. As shown in Fig. 4E ,G, the increased production of neurons upon GPR157 overexpression was partially but significantly reversed by co-expression of Gα q-CT and IP 3 sponge. Moreover, nearly 40% of Gα q Q209L-expressed cells were TUJ1-positive whereas the effect was counterbalanced by co-expression of IP 3 sponge (Fig. 4F,H) . When the cultures were pulse labeled with BrdU, no significant difference in populations of BrdU-positive cells among GFP-and SOX2-postive cells was found at any condition ( Supplementary Fig. S9 ). Also, there was no significant difference in the percentage of apoptotic cells among the GFP-positive cells at any condition (< 1%). These results indicate that GPR157-Gq-IP 3 signaling contributes to neuronal differentiation of RGPs.
Putative ligand(s) of GPR157 are present in the CSF. The localization of GPR157 at the cilium exposed to the CSF suggests the possible existence of putative ligand(s) for the orphan receptor in the fluid. To investigate this possibility, we measured the ability of the CSF to activate GPR157 in U-2 OS cells using the Alkaline Phosphatase-TGFα shedding assay 28 . In this GPCR assay system, GPR157 was transfected into U-2 OS cells, together with TGFα whose ectodomain is fused with Alkaline Phosphatase (AP-TGFα ). Upon ligand binding to GPR157, endogenous TACE is activated by Gq and cleaves TGFα ectodomain, resulting in AP release into the media. The ratio of AP activity in the media to total AP activity was measured and defined as GPR157-activation index (also called relative AP activity). Using the assay system, we measured the relative AP activity of the CSF collected from the lateral ventricles of embryonic brains at E10 and E13. When E13 CSF was applied to GPR157-transfected and mock-transfected cells, the relative AP activity of GPR157-transfected cells was significantly higher than that of mock-transfected cells (Fig. 5A) . On the other hand, when HBSS was applied to the cells, no significant difference in the relative AP activity was found between GPR157-and mock-transfected cells (Fig. 5A) . A slightly higher relative AP activity of mock-transfected cells supplemented with E13 CSF was found when compared to that obtained with HBSS (Fig. 5A ). This effect is likely due to activation of endogenous GPCR signaling in U-2 OS cells in response to E13 CSF. Importantly, E13 CSF was significantly more potent to activate GPR157 than E10 CSF (Fig. 5A) . These results suggest that putative ligand(s) of GPR157 exist in the CSF and that ability of the CSF to activate GPR157 is higher at E13 than at E10. Finally, we examined the neurogenic potential of E13 CSF in RGP cultures. For this purpose, BrdU-labeled RGPs were cultured with either E10 or E13 CSF for 2 days and then immunostained with TUJ1 and SOX2 antibodies. We found that E13 CSF gave rise to more TUJ1-positive neurons (approximately 30%) than E10 CSF (approximately 20%) (Fig. 5B,C) . These results indicate that E13 CSF has neurogenic potential more than E10 CSF.
Discussion
The fate of RGPs is controlled by local environmental signals borne by a variety of sources in a developmental stage-dependent manner. The identification of molecules, their sources and signaling pathways responsible for this control is primordial for our understanding of the mechanisms underlying neurogenesis and brain development.
In the present study, we find that GPR157, an orphan GPCR with no subfamily and splice variant reported to date, is expressed in the developing neocortex. Using a home-made specific antibody (Fig. 1D, Supplementary  Figs S1 and S2) , we revealed that GPR157 is localized in the primary cilia of RGPs that protrudes into the CSF. Importantly, we found that GPR157 is coupled with Gq-class G-proteins and that GPR157-Gq-IP 3 signaling contributes to neuronal differentiation of RGPs. This was supported by finding of decreased neuronal differentiation of RGPs in vivo upon depletion of GPR157, inactivation of Gq and overexpression of IP 3 sponge that sequesters IP 3 and suppress IP 3 -dependent Ca 2+ release from Ca 2+ stores. Using cultured primary RGPs we also showed (A,B) respectively. Data are presented as mean ± s.e.m. (n = 3). *p < 0.05, **p < 0.01. Scale bars: 50 μ m. (E) Plasmids expressing GPR157, both GPR157 and Gα q-CT, both GPR157 and IP 3 sponge, Gα q-CT, or IP 3 sponge were electroporated, together with the GFP-expressing plasmid, into E13 embryos. Cortical cells were prepared, cultured for 3 days, and immunostained with antibodies against SOX2 and TUJ1. (F) Plasmids expressing Gα q Q209L or both Gα q Q209L and IP 3 sponge were electroporated, together with the GFP-expressing plasmid, into E13 embryos. Cortical cells at 3DIV were immunostained as in (E). (G,H) The graph showing the fraction of GFP-positive cells that were also positive for SOX2 or TUJ1 in (E) and (F) respectively. Data are presented as mean ± s.e.m. (n = 4; more than 100 cells were analyzed in each condition). *p < 0.05, **p < 0.01, ***p < 0.001. . The CSF contains a wide variety of signaling molecules, and its constituents dynamically change throughout brain and spinal cord development 12 . Thus, the CSF is expected to have an active role (e.g., regulation of RGPs biology) beyond providing a fluid cushion for the CNS and maintenance of extracellular ionic balance. In fact, CSF-borne signals have been shown to regulate RGP proliferation 32 . The present study found that GPR157 is present at the primary cilium, and at least one constituents in the CSF can activate GPR157. Intriguingly, its ability to activate GPR157 increases at neurogenic phase (E13), when compared to proliferative phase (E10) (Fig. 5A) . This suggests that GPR157-mediated signaling is switched on during the neurogenic phase by virtue of developmentally regulated factor(s) in the CSF yet to be determined. Of note, GPR157 depletion in RGPs at E13 reduced their neuronal differentiation in vivo (Fig. 2) , but overexpression of GPR157 (GPR157 res ) does not enhance it any further. In contrast, overexpression of GPR157 in cultured RGPs derived from E13 neocortices promoted their neuronal differentiation (Fig. 4E,G) . These observations led us to propose the idea that GPR157-mediated signaling is sufficiently activated by CSF factor(s) in vivo at E13 but minimal in cultured RGPs devoid of the CSF. In mice, the amniotic fluid is trapped into the neural tube at neural tube closure (around E9) and serves as the initial CSF. Around E11 the choroid plexus starts to develop and produces the CSF 33, 34 . As the choroid plexus is expected to be a source of many signaling factors 8, 35 , ligand(s) for GPR157 in the E13 CSF may derive from this secretory structure.
In conclusion, the present study identifies GPR157 located at the primary cilium as a transducer of signals derived from CSF during neurogenic phase, and a modulator for neuronal differentiation of RGPs. Several RGPs-specific GPCRs including GPR157 have recently been identified by RNA-seq 36, 37 . Further analysis of the GPCR-Gα signaling cascades and the identification of ligand(s) for GPR157 will pave the way for deciphering the complex mechanisms underlying the RGPs-CSF interface in the developing neocortex.
Methods
Plasmids. The plasmid expressing GFP under the control of the CAG promoter (pCAGIG) and pCAGEN plasmid that directs cloned gene expression from the CAG promoter were kind gifts from Takahiko Matsuda (Kyoto University, Kyoto, Japan). Plasmid encoding Gα q-CT (expressing Arg306-Val359 of Gα q) in pCAGGS plasmid was a generous gift from Yoh Takuwa (Kanazawa University, Ishikawa, Japan). pBS/U6 plasmid was kindly provided by Yang Shi (Harvard Medical School, MA, USA). pAlph-TGF-alpha plasmid was generously provided by Shigeki Higashiyama (Ehime University, Ehime, Japan).
Plasmid expressing Lifeact-EGFP 21 was generated by inserting the fragment encoding MGVADLIKKFESISKEE-EGFP into the pCAGEN plasmid. The full-length open reading frame of mouse Gpr157 was cloned into the pCAGEN plasmid. A plasmid encoding a silent mutant of GPR157 was generated by the QuikChange mutagenesis technique using primers 5′ -GCGTCCTTCAGGGCGC TCTATCTACCTTCGCCAACACCAGC-3′ (forward) and 5′ -GCTGGTGTTGGCGAAGGTAGA TAGAGCGCCCTGAAGGACGC-3′ (reverse). A plasmid encoding Gα q Q209L (CloneID: GNA0Q000C0) was purchased from UMR (University of Missouri-Rolla).
For constructing a plasmid expressing IP 3 sponge, IP 3 -binding regions of mouse IP 3 R1 (residues 224-604) 27 was cloned into the pCAGEN plasmid. Plasmids encoding GPR157 shRNA were generated by inserting the annealed oligonucleotides into the pBS/U6 plasmid 38 . Oligonucleotides used were as follows: GPR157 shRNA #1, 5′-GGTGTCCCGTTGGCCATCACAAGCTTGTGATGGCCAACGGGACACCCTT TTTG-3′ and 5′-AATTCAAAAAGGGTGTCCCGTTGGCCATCACAAGCTTGTGATGGCCAACGGGACACC-3′ ; GPR157 shRNA#2, 5′-GGCGCTCTCTCTACTTTCGCAAGCTTGCGAAAGTAGAGAGAGCG CCCTTTTTG-3′ and 5′-AATTCAAAAAGGGCGCTCTCTCTACTTTCGCAAGCTTGCGAAAGTA GAGAGAGCGCC-3′ .
In utero electroporation. DNA solution (~1 μ l) in PBS containing 0.02% fast green was injected into the lateral ventricle of the embryos. After injection, electroporation (four 50 ms square pulses of 40 V and 950 ms intervals for E13 embryo, four 50 ms square pulses of 45 V and 950 ms intervals for E14 embryo, four 30 ms square pulses of 45 V and 970 ms intervals for E11 embryo; Nepa Gene, CUY21-EDIT) was carried out with forceps-type electrodes (Nepa Gene, CUY650P5 for E13 and CUY650P3 for E11 and E14) using ICR mice. Final concentrations of the plasmids used were: GFP-expressing plasmid (pCAGIG: 4 μ g/μ l), Lifeact-EGFP-expressing plasmid (0.8 μ g/μ l), control shRNA plasmid (pBS/U6: 4 μ g/μ l), GPR157 shRNA plasmid (4 μ g/μ l), plasmid expressing silent mutant GPR157 (3.2 μ g/μ l), GPR157-expressing plasmid (4 μ g/μ l), Gα q Q209L-expressing plasmid (4 μ g/μ l) Gα q-CT-expressing plasmid (8 μ g/μ l and 4 μ g/μ l for neocortical cell culture) and IP 3 sponge-expressing plasmid (10.5 μ g/μ l and 4 μ g/μ l for neocortical cell culture). For BrdU-labeling experiments, pregnant dams were injected with BrdU (100 mg per gram of body weight at E15) for 30 minutes before harvest. All animal experiments were conducted in accordance with guidelines set by The University of Tokyo and approved (permit number 21-01) by the Committee on Animal Care and Use of the Graduate School of Science in The University of Tokyo.
GPR157 antibody production and immunostaining. Antibody against GPR157 was generated by Sigma Aldrich as follows. Synthetic peptides corresponding to amino acids Lys314-Ser329 of GPR157 were conjugated to keyhole limpet hemocyanin and used to immunize rabbits. GPR157 antibody was affinity-purified from the serum by a column coupled with synthetic peptides Lys314-Ser329. For immunostaining of E13, E17, P0, and Adult coronal brain sections with anti-GPR157, brains were fixed with 4% paraformaldehyde in PBS overnight at 4 °C. Thereafter, the brain sections (40 μ m) were prepared with a vibratome, followed by immunostaining. For immunostaining of E10 coronal brain sections with anti-GPR157, brains were fixed with 4% paraformaldehyde in PBS overnight at 4 °C. Thereafter, the brain sections (40 μ m) were prepared with a cryostat, followed by immunostaining. For imaging en face view of the lateral ventricle, telencephalic hemispheres were fixed as describe above and pretreated with HistoVT One solution (Nacalai Tesque) for 15 minutes at 70 °C. Thereafter, the telencephalic hemispheres were immunostained and mounted with the ventricular surface upward.
Antibodies. Primary antibodies used for immunostaining were as follows: rabbit anti-GPR157 (1:100), Primary antibodies used for immunoblotting were as follows: rabbit anti-GPR157 (1:1000), rabbit anti-GFP (1:1000, A-11122; Thermo Fisher), and mouse anti-β -actin (1:15000, A1978; Sigma Aldrich).
Immunohistochemistry. Brain sections were immunostained as described previously 39 . For staining with PAX6, TBR2, SOX2, and S100β brain sections were pretreated with HistoVT One solution for 15-20 minutes at 70 °C. For staining with BrdU, brain sections were pretreated with 4 N HCl for 25 minutes at room temperature. Images were obtained with a 63× objective (Plan-Apochromat, Zeiss) on a Zeiss LSM5 confocal microscope.
Cell culture, transfection and cell-based analyses. For evaluation of GPR157 knockdown by shRNA constructs, U-2 OS cells maintained in DMEM/10% FBS were transiently transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Transfections were allowed to proceed for 4-5 hours, and then cells were cultured in 10% FBS/DMEM for 24 hours. The cells were then subjected to immunoblotting.
For neocortical cell culture, E13 embryos were electroporated with plasmids encoding GFP (pCAGIG), GPR157, Gα q-CT, Gα q Q209L, and IP 3 sponge. Following electroporation, neocortical cells were prepared as described 40 , plated at a density of ~2.0 × 10 5 cells on sterile coverslips precoated with Poly-D-lysine in wells of 24-well plates and maintained in DMEM/Ham's F12 (D-Glucose concentration; 0.6% [w/v]) supplemented with 1% penicillin-streptomycin, 2% B27, 1% N2 and 10 ng/ml bFGF. For analysis of the identity of electroporated RGPs in vitro, neocortical cells were fixed at 3 days in vitro (DIV3) with 4% paraformaldehyde in PBS for 20 minutes at 37 °C, permeabilized with 0.2% Triton X-100 in PBS for 5 minutes, and blocked with 3% BSA/0.2% Triton X-100 in PBS, followed by incubation with primary antibodies diluted in the blocking solution overnight at 4 °C. The coverslips were then incubated with Alexa 488/Cy3/Cy5-conjugated secondary antibodies overnight at 4 °C and mounted in a Prolong Gold mounting solution. For analysis of CSF's effect on neuronal differentiation of cultured RGPs, neocortical cells were prepared from E13 brains, plated at a density of ~1.4 × 10 3 cells in wells 60-well Nunclon Minitray (Nunc) of precoated with Poly-D-lysine. Cells were maintained for 1 day in culture media [DMEM/Ham's F12 supplemented with D-Glucose (final concentration 0.6% [w/v]), 1% penicillin-streptomycin, 2% B27, 1% N2 and 10 ng/ml bFGF. Thereafter, BrdU (final concentration 10 μ M) was added to the media and incubated for 1 hour. The culture media were replaced with artificial CSF (NaCl 119 mM, KCl 2.5 mM, NaHCO 3 26 mM, NaH 2 PO 4 1 mM, glucose 11 mM, MgCl 2 2 mM, CaCl 2 2.8 mM) or CSF (1/2 dilution with culture media). Neocortical cells cultured for 2days were then fixed and followed by immunostaining. For BrdU-labeling experiments, BrdU (final concentration 10 μ M) was added to the media and incubated for 1 hour before fixation. After fixation, neocortical cells were pretreated with 2 N HCl for 30 minutes at room temperature.
RT-PCR.
Total RNA from mouse neocorticies was prepared by using RNA easy (Quiagen) according to the manufacturer's protocol. Total RNA was reverse transcribed with Superscript II (Invitrogen) and an anchored (dT)16 primer. The obtained cDNAs were subjected to PCR (Applied Biosystems) by using gene-specific primers.
Primers used were as follows: Beta-actin-Fw, 5′ -CCTTCTACAATGAGCTGCGTGTG-3′ ; Beta-actin-Rv 5′ -AGAGGCATACAGGGACAGCACAG-3′ ; Nestin-Fw 5′ -GCTGAGAACTCTCGCTTGCAGAC-3′ ; Nestin-Rv 5′ -AAGAGAAGGATGTTGGGCTGAGG-3′ ; GPR157-Fw 5′ -TTGGTCAGAAAGCACATCAACAG-3′ ; GPR157-Rv 5′ -TGCTTGGTCTCCTAATCCTGAAG-3′ .
Calcium assay. U-2 OS cells were plated at a density of 1.0 × 10 5 cells in wells of 35 mm glass bottom dish (Matsunami) and maintained in DMEM/10% FBS for 24 hours before transfection. U-2 OS cells were transiently transfected with Lipofectamine 2000. Transfections were allowed to proceed for 4-5 hours, and then cells were cultured in 10% FBS/DMEM. Twenty-four hours later, changes in [Ca 2+ ] i were measured by using Screen Quest Rhod-4 NW Calcium Assay Kit (AAT Bioquest) according to the manufacturer's instructions. In brief, culture medium was replaced with Rhod-4 dye-loading solution, and cells were incubated for 1 hour. Thereafter, the solution was replaced with DMEM without phenol-red after rinsing once. Rhod4 fluorescent images were obtained with 20× objective (EC Plan-Neofluar, Zeiss) on a Zeiss Axio Observer.A1 microscope, and the Rhod4 fluorescent intensity in GFP-labeled cells were measured by using Fiji software. In addition, background fluorescent intensity was also measured in the area with no cells present, was subtracted from Rhod4 measurements. The subtracted Rhod4 measurements were plotted in the graphs. ] i were measured as described above.
AP-TGFα shedding assay. AP-TGFα shedding assay were performed as described previously 27 with modifications. U-2 OS cells were seeded in wells of 24-well plates at a density of 1.0 × 10 5 cells/well and maintained in DMEM/10% FBS for 24 hours. The cells were then transiently transfected with plasmids (a mixture of 500 ng/ well AP-TGFα plasmid, 150 ng/well GPCR plasmid and 25 ng/well mCherry plasmid) using Lipofectamine 3000. Twenty-four hours later, the cells were rinsed once with PBS, treated with 100 μ l of PBS containing 0.05% (w/v) trypsin and 0.20 mM EDTA for several minutes, and suspended with 950 μ l DMEM/10% FBS. Small aliquots (105 μ l) of the cell suspension were re-seeded in wells of 96-well plates. Twenty-four hours later, the cells were serum-starved for one day with DMEM/0.05%FBS. Thereafter, the cells were rinsed twice with HBSS and then treated with either 30 μ l of HBSS or CSF (1:8 dilution with HBSS) for 1 hour at 37 °C. After the incubation, 70 μ l of HBSS were added to each well, and 80 μ l of the solution were collected into empty wells. p-NPP-containing solution (80 μ l) were then added into individual wells. The absorbance at 405 nm was measured immediately and after 1 hour at 37 °C. Relative percentage of AP activity in conditioned medium was calculated as 28 . Samples of CSF were collected from the lateral ventricle as described 41 .
Statistical analysis. Statistical analyses were carried out with Excel (Microsoft). Sample sizes were based on previous experiments. All data are shown as mean ± s.e.m. Comparison of two groups was analyzed using Welch's t-test. P < 0.05 was considered statistically significant.
